Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Evaluation of Small Molecule EGFR-1 Tyrosine Kinase Inhibition as a First-Line Treatment in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Harbouring a Mutant EGFR Gene

NCT00339586 is registered in ClinicalTrials.gov with Universitair Ziekenhuis Brussel as lead sponsor.

NCT NCT00339586
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00339586 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Evaluation of Small Molecule EGFR-1 Tyrosine Kinase Inhibition as a First-Line Treatment in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Harbouring a Mutant EGFR Gene
Lead sponsor
Universitair Ziekenhuis Brussel
Phase
Phase 2
Overall status
Unknown status
Start date
January 31, 2006
Completion date
Not reported
Enrollment
40
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma, bronchiolo-alveolar, lung neoplasms, non-small cell lung cancer